Klin Onkol 2015; 28(Suppl 3): 87-94. DOI: 10.14735/amko20153S87.
Hodgkin’s lymphoma is a relatively rare malignant disease, mostly affecting younger adults. It represents one of the most curable disease among all lymphomas and other malignant dis eases of adult age, with curability more than 80%. The progress of curability and long term survival demonstrates the development of oncologic approach during the last few decades, depicted in this article, particularly by introduction of combined modality treatment (chemotherapy and radiotherapy), progress in radiotherapy technique, implementation of high intensity regimens for advanced stages and use of novel drugs as well. Because of high curability rate and young age of most of the patients, late toxic effects are of significant relevance. The ongoing clinical research is focused on better prognostic stratification offering the patients more individualized treatment by risk and response disease evaluation, aiming to reduce toxicity while maintaining high curability and introduction of novel, less toxic drugs and their use in early phases of treatment.